APG-115

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
69 patients (estimated)
Sponsors
Ascentage Pharma Group Inc.
Tags
Antimetabolites, Hypomethylating Agents (HMA), MDM2 Inhibitor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1371
NCT Identifier
NCT04358393

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.